Aura Biosciences, Inc. (AURA)
7.20
-0.16
(-2.17%)
USD |
NASDAQ |
Sep 09, 15:48
Aura Biosciences Debt to Equity Ratio : 0.0526 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0526 |
| March 31, 2026 | 0.1584 |
| December 31, 2025 | 0.1269 |
| September 30, 2025 | 0.1133 |
| June 30, 2025 | 0.1037 |
| March 31, 2025 | 0.1441 |
| December 31, 2024 | 0.1235 |
| September 30, 2024 | 0.1093 |
| June 30, 2024 | 0.0994 |
| March 31, 2024 | 0.0925 |
| December 31, 2023 | 0.0866 |
| September 30, 2023 | 0.1331 |
| Date | Value |
|---|---|
| June 30, 2023 | 0.1227 |
| March 31, 2023 | 0.1145 |
| December 31, 2022 | 0.1066 |
| September 30, 2022 | 0.1831 |
| June 30, 2022 | 0.0053 |
| March 31, 2022 | 0.0059 |
| December 31, 2021 | 0.0064 |
| September 30, 2021 | 0.0133 |
| June 30, 2021 | 0.0136 |
| March 31, 2021 | 0.0085 |
| December 31, 2020 | 0.0008 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
| Oncolytics Biotech, Inc. | -0.0726 |
| Sangamo Therapeutics, Inc. | -1.020 |
| Sarepta Therapeutics, Inc. | 0.6845 |
| Anixa Biosciences, Inc. | 0.0127 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 348.13M |
| Total Liabilities (Quarterly) | 32.86M |
| Shareholders Equity (Quarterly) | 315.27M |
| Current Ratio | 16.82 |
| Net Debt Paydown Yield | 0.05% |